Impact of somatostatin analogues on quality of life in patients with neuroendocrine tumours

2017 ◽  
Author(s):  
Tahir Shah ◽  
Hannah Osborne ◽  
Stacey Smith ◽  
Vandana Sagar
Keyword(s):  
Quality Of Life ◽  
Neuroendocrine Tumours ◽  
Somatostatin Analogues

scholarly journals Impact of Specific Bowel Symptoms on Quality of Life in Patients with Midgut Neuroendocrine Tumours

2021 ◽  
Author(s):  
Håkan Ohlsson ◽  
Gideon Wahlberg ◽  
Marlene Malmquist ◽  
Rita Gustafsson ◽  
Anna Sundlöv ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Neuroendocrine Tumours ◽  
Bowel Function ◽  
Charlson Comorbidity Index Score ◽  
Bowel Symptoms ◽  
Hrqol Questionnaire ◽  
Related Quality ◽  
Eortc Qlq ◽  
Midgut Net

Abstract Introduction Patients with midgut neuroendocrine tumours (NETs) suffer from decreased health-related quality of life (HRQoL), in large part due to bowel symptoms. However, it is unknown which bowel symptoms affect HRQoL the most. An enhanced understanding of this is essential to better focus treatment on this aspect of the disease. This study aimed to determine which bowel symptoms affect HRQoL the most in patients with midgut NETs. Methods Consenting patients with midgut NET completed the Memorial Sloan Kettering Bowel Function Instrument and the HRQoL questionnaire (EORTC QLQ-C30). The correlation between bowel symptoms and HRQoL was analysed using multiple linear regression, adjusting for age, Charlson Comorbidity Index score, presence of metastatic disease, chromogranin A, and BMI yielding ß-coefficients with 95% confidence intervals. Results Totally, 119 patients with midgut NET completed the questionnaires and were included in the study. Loose stool and bowel frequency ≥ 3/day were the most common bowel symptoms, reported by 47% and 56% of patients, respectively. However, sensitivity to certain types of food and beverages, a feeling of incomplete emptying of the bowel, and soiling were the symptoms most strongly correlated with decreased HRQoL, especially within domains concerning role and social function, with ß-coefficients for the strongest correlated symptoms of 15.0 and 14.6, respectively. Discussion While symptoms concerning stool consistency and frequency are common in patients with midgut NET, our study suggests that other, more socially stigmatising symptoms affect patients’ HRQoL more. Our findings could help caregivers understand patients’ perceptions of the disease and provide avenues for more directed therapies.

scholarly journals Neuroendocrine tumours: what gastroenterologists need to know

2020 ◽  
pp. flgastro-2020-101431
Author(s):  
Mohid S Khan ◽  
D Mark Pritchard
Keyword(s):  
Quality Of Life ◽  
Neuroendocrine Tumours ◽  
Comprehensive Evaluation ◽  
Treatment Options ◽  
Somatostatin Analogue ◽  
Low Grade ◽  
Multiple Treatment ◽  
Gastrointestinal Problems ◽  
Patient Reported

Gastroenterologists are intermittently involved in diagnosing and managing patients who have neuroendocrine tumours (NETs). However, few UK gastroenterologists have received extensive training about this topic. This article aims to provide a brief introduction to NETs; it is aimed at a general gastroenterologist audience.NETs present in diverse ways and many symptomatic patients unfortunately experience significant delays in diagnosis. Comprehensive evaluation of a patient with a possible NET involves assessing their symptoms, the tumour’s primary organ of origin, its differentiation status, grade and stage, whether the NET is secreting hormones and whether there is any underlying hereditary predisposition. Such assessment often needs specialist investigations such as nuclear medicine scans. All these factors influence patient management and prognosis, so a patient’s case and investigations should always be discussed by a fully constituted NET multidisciplinary team. Most localised tumours are considered for resection, but there are multiple treatment options for metastatic disease and many patients receive several different therapies during the course of their illness. The most common first line treatment in patients who have metastatic low grade NETs is monthly long acting somatostatin analogue injections. Prognosis is highly variable, but some patients who have inoperable metastases survive for many years on treatment with good quality of life. Gastroenterologists may also be involved in managing the non-tumour associated chronic gastrointestinal problems that some patients experience. Their involvement has been shown to improve patient-reported outcomes and quality of life.

scholarly journals The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Carlo Garofalo ◽  
Ivana Capuano ◽  
Luigi Pennino ◽  
Ilaria De Gregorio ◽  
Eleonora Riccio ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Liver Disease ◽  
Sample Size ◽  
Meta Analysis ◽  
Liver Volume ◽  
Somatostatin Analogues ◽  
Adult Patients ◽  
Polycystic Liver Disease ◽  
Polycystic Liver

AbstractA clear evidence on the benefits of somatostatin analogues (SA) on liver outcome in patients affected by polycystic liver disease is still lacking. We performed a meta-analysis of RCTs and a trial sequential analysis (TSA) evaluating the effects of SA in adult patients with polycystic liver disease on change in liver volume. As secondary outcome, we evaluated the effects on quality of life as measured by SF36-questionnaire. Six RCTs were selected with an overall sample size of 332 adult patients with polycystic liver disease (mean age: 46 years). Mean liver volume at baseline was 3289 ml in SA group and 3089 ml in placebo group. Overall, unstandardized mean difference in liver volume was − 176 ml (95%CI, − 406, 54; p < 0.133). Heterogeneity was low (I2:0%, p < 0.992). However, we performed a moderator analysis and we found that a higher eGFR significantly correlates to a more pronounced effect of SA on liver volume reduction (p = 0.036). Cumulative Z-curve in TSA did not reach either significance and futility boundaries or required information size. Three RCTs have evaluated Quality of life parameters measured by SF36-QOL questionnaire for a total of 124 patients; no significant difference was found on the effect of SA on QOL parameters when compared with placebo. The present meta-analysis revealed a potential effect of SA on reduction of liver volume and quality of life parameters, but results did not reach a statistical significance. These data could be explained by the need of further studies, as demonstrated through TSA, to reach an adequate sample size to confirm the beneficial outcomes of SAs treatment.

scholarly journals Quality of life in patients with acromegaly based on the AcroQoL questionnaire

2018 ◽  
Vol 46 (3) ◽  
pp. 233-239
Author(s):  
A. V. Dreval ◽  
Yu. G. Pokramovich ◽  
I. A. Ilovayskaya ◽  
A. D. Gilyazova
Keyword(s):  
Quality Of Life ◽  
Radiation Treatment ◽  
Age Groups ◽  
Treatment Strategies ◽  
Specific Treatment ◽  
Somatostatin Analogues ◽  
Published Data ◽  
Validated Questionnaire ◽  
Potential Factors

Rationale: International experts emphasize that treatment strategies for patients with acromegaly should be aimed not only at normalization of biochemical parameters, but also at the achievement of better health-related quality of life (HRQL). However, the published data on the quality of life in patients with acromegaly is scarce.Aim: To assess HRQL in patients with acromegaly with a disease-specific validated questionnaire (AcroQoL) and to identify potential factors that may influence it.Materials and methods: One hundred fourteen (114) patients aged from 18 to 83 years (median age, 56 years, interquartile range, 46 to 63). All patients were divided into the age groups, as well as into the groups depending on the treatment they had received and on the control of acromegaly.Results: In the whole group of the patients (n = 114), the levels of insulin-like growth factor I significantly (p = 0.026) correlated with the domain “personal relationships”. When the patients with newly diagnosed acromegaly (n = 34) were compared to those who had been previously treated (n = 80), there were significant differences for “HRQL global” (p = 0.015) and “physical dimension” (p = 0.009). HRQL of the patients with controlled (n = 37) acromegaly did not differ from HRQL of those with uncontrolled disease (n = 43) (p > 0.05). Surgery and radiation treatment had no impact on the patients' HRQL (p > 0.05), whereas the treatment with somatostatin analogues improved only its physical dimension (p = 0.034).Conclusion: Treatment interventions do not improve quality of life in patients with acromegaly. This can be explained as follows: modern treatment approaches (surgery, radiation) do not lead to immediate noticeable results, whereas treatment-related complications can manifest themselves clearly. As a result, the patient may get an impression that his/ hers quality of life has not improved, despite the fact that the expediency of the specific treatment administered has been absolutely proven.

Sign in / Sign up

Export Citation Format

Share Document